Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin + metronidazole for induction of remission in active pediatric Crohn's disease
NL-OMON39861Phase 3Active, not recruiting
- Sponsor
- Edith Wolfson Medical Center
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Crohn's disease and inflammatory bowel disease (IBD) comparing Azithromycin + metronidazole with Metronidazole (2 arms). Primary endpoint: Response rate at 8 weeks. Started Oct 2014; status: active, not recruiting.
02
Drugs
azithromycinmetronidazole
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON39861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39861.